A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma

mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib

(2017) Tim Meyer et al.   LIVER INTERNATIONAL

Systemic therapy in HCC: Lessons from brivanib

(2014) David Bolos et al.   JOURNAL OF HEPATOLOGY

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Systemic therapies in hepatocellular carcinoma: present and future

(2013) Gaetano Bertino et al.   Future Oncology

Fibroblast growth factor signaling in liver carcinogenesis

(2013) Dalbir S. Sandhu et al.   HEPATOLOGY

The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?

(2013) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma

(2012) Hashem B. El-Serag   GASTROENTEROLOGY

Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma

(2012) Augusto Villanueva et al.   HEPATOLOGY

Targeted therapy of hepatocellular carcinoma: Present and future

(2012) Stephen L Chan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

HCC and angiogenesis: possible targets and future directions

(2011) Andrew X. Zhu et al.   Nature Reviews Clinical Oncology

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

(2011) Peter Stopfer et al.   XENOBIOTICA

Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma

(2010) Winnie Yeo et al.   BMC CANCER

Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2+pTyr+ Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker In Vivo

(2010) Kanae Kudo et al.   CLINICAL CANCER RESEARCH

Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion

(2010) Pei-Jer Chen et al.   LIVER INTERNATIONAL

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

(2010) S Whittaker et al.   ONCOGENE

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

(2010) Riccardo Lencioni et al.   SEMINARS IN LIVER DISEASE

Hepatocellular carcinoma in the Asia pacific region

(2009) Man-Fung Yuen et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE